Yongyi Zeng
机构：Fujian Medical University, Mengchao Hepatobiliary Hospital · ORCID：0000-0001-8823-698X
发表论文 50 篇 · 总被引 1691 次 · h-index 16
代表论文
- Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet · 被引 282)
- Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial (2025 · The Lancet · 被引 54)
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 51)
- Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) (2024 · BioScience Trends · 被引 21)
- Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma (2024 · Advanced Science · 被引 21)
- Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, open-label, randomized, phase 2 study (CAP-ACE). (2025 · Journal of Clinical Oncology · 被引 13)